Mesoblast limited (ASX:MSB) insider William (Bill) Burns acquired 32,670 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were bought at an average cost of A$1.83 ($1.30) per share, with a total value of A$59,786.10 ($42,401.49).

MSB opened at A$1.92 ($1.36) on Friday. The firm has a 50-day simple moving average of A$1.81 and a two-hundred day simple moving average of A$1.64. Mesoblast limited has a 52 week low of A$1.02 ($0.72) and a 52 week high of A$2.23 ($1.58). The company has a market capitalization of $955.93 million and a PE ratio of -12.60. The company has a quick ratio of 0.74, a current ratio of 0.86 and a debt-to-equity ratio of 18.77.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Featured Article: What is an investor looking for in an SEC filing?

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.